Afrin Antara, Cohen Philip R
Dermatology, Michigan State University College of Human Medicine, East Lansing, USA.
Dermatology, University of California, Davis Medical Center, Sacramento, USA.
Cureus. 2022 Apr 2;14(4):e23754. doi: 10.7759/cureus.23754. eCollection 2022 Apr.
Drug-induced hyperpigmentation is an adverse cutaneous effect; it has been associated with several systemic medications. A healthy 40-year-old man developed facial and dorsal hand hyperpigmentation within two weeks of beginning doxycycline monohydrate 100 milligrams twice daily for acne. Skin pigmentation significantly diminished at a follow-up evaluation two months after discontinuing the medication. Doxycycline-associated skin hyperpigmentation, albeit uncommon, has been described in 18 patients in the literature, including our patient. The demographics included 13 males and five females ranging in age from 11 to 87 years; eight of the patients were less than 50 years old and ten of the patients were over 60 years old. Doxycycline-associated hyperpigmentation frequently occurs on the face and can occur at the site of a previous scar. In most cases, doxycycline was discontinued with the resolution of hyperpigmentation.
药物性色素沉着是一种不良皮肤效应;它与多种全身性药物有关。一名40岁健康男性在开始每日两次服用100毫克一水合多西环素治疗痤疮两周内,面部和手部背部出现色素沉着。停药两个月后的随访评估中,皮肤色素沉着明显减轻。多西环素相关的皮肤色素沉着虽不常见,但文献中已报道18例患者,包括我们的患者。这些患者的人口统计学特征包括13名男性和5名女性,年龄从11岁到87岁不等;其中8名患者年龄小于50岁,10名患者年龄大于60岁。多西环素相关的色素沉着常发生在面部,也可发生在既往瘢痕部位。在大多数情况下,停用多西环素后色素沉着会消退。